Literature DB >> 2939867

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.

P Lund-Johansen, P Omvik, H Haugland.   

Abstract

The acute and chronic haemodynamic effects of doxazosin were studied in 14 patients (10 males, four females) with essential hypertension, at rest supine and sitting and during 100 W bicycling exercise. Blood pressure (BP) was recorded intra-arterially in the brachial artery, cardiac output (CO) was measured by Cardiogreen and heart rate (HR) by ECG. One hour after injection of doxazosin 0.5-1.0 mg i.v., mean arterial pressure (MAP) was reduced by 8% at rest supine, 12% at rest sitting and 10% at 100 W (all changes statistically significant), associated with a reduction in total peripheral resistance index (TPRI) of 5% at rest supine, 9% at rest sitting (P less than 0.01) and 14% at 100 W (P less than 0.001). HR was slightly increased (5%, NS) and cardiac index (CI) was unchanged during rest and slightly increased during exercise (4%, P less than 0.05). Patients were then given doxazosin capsules (2-16 mg once daily), aiming at a casual BP of less than or equal to 140/90 mmHg without side-effects. Central haemodynamics were restudied after 1 year. After 1 year of doxazosin treatment, MAP was reduced by 13% at rest supine, 16% at rest sitting and 17% at 100 W (all P-values less than 0.001). TPRI was reduced by 19% at rest supine, 20% at rest sitting and 18% at 100 W (all changes statistically significant). CI was increased by 8% at rest supine (P less than 0.05) but was unchanged sitting and at 100 W. It is concluded that doxazosin lowers BP through a reduction in TPRI acutely as well as chronically, without reductions in CO. BP control was maintained over 1 year without side-effects. Thus, doxazosin normalizes central haemodynamics in patients with mild to moderate essential hypertension, both at rest and during exercise.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939867      PMCID: PMC1400746          DOI: 10.1111/j.1365-2125.1986.tb02853.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Central and renal circulation, renin and aldosterone in plasma during prazosin treatment in essential hypertension.

Authors:  D K Falch; A Q Paulsen; A E Odegaard; N Norman
Journal:  Acta Med Scand       Date:  1979

2.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

3.  Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities.

Authors:  P B Timmermans; H Y Kwa; F K Ali; P A van Zwieten
Journal:  Arch Int Pharmacodyn Ther       Date:  1980-06

4.  Determination of extracellular fluid volume in uremic patients by oral administration of radiosulfate.

Authors:  P Omvik; R C Tarazi; E L Bravo
Journal:  Kidney Int       Date:  1979-01       Impact factor: 10.612

5.  The alpha 1- and alpha 2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat.

Authors:  P J Beckett; L Finch
Journal:  Eur J Pharmacol       Date:  1982-08-27       Impact factor: 4.432

6.  A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.

Authors:  H L Elliott; P A Meredith; D J Sumner; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

7.  Borderline hypertension: relationship between age, hemodynamics and circulating catecholamines.

Authors:  F H Messerli; E D Frohlich; D H Suarez; E Reisin; G R Dreslinski; F G Dunn; F E Cole
Journal:  Circulation       Date:  1981-10       Impact factor: 29.690

8.  Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise.

Authors:  P Omvik; P Lund-Johansen
Journal:  J Hypertens       Date:  1983-12       Impact factor: 4.844

9.  Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man.

Authors:  W Singleton; C A Saxton; J Hernandez; B N Prichard
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension.

Authors:  S G Chrysant; R F Miller; J L Brown; K Danisa
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

View more
  16 in total

1.  Long-term hemodynamic effects of antihypertensive treatment.

Authors:  P Lund-Johansen; P Omvik; J E Nordrehaug
Journal:  Clin Investig       Date:  1992

2.  Long-term haemodynamic effects of sustained-release trimazosin at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?

Authors:  M Ligueros; R Unwin; M Wilkins
Journal:  Clin Auton Res       Date:  1991-09       Impact factor: 4.435

4.  A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.

Authors:  M Ligueros; R Unwin; M R Wilkins; J Humphreys; S J Coles; J Cleland
Journal:  Clin Auton Res       Date:  1992-12       Impact factor: 4.435

Review 5.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

6.  Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 7.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

8.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

9.  Doxazosin versus nitrendipine: a double-blind comparative study in patients adhering to a sodium-restricted diet.

Authors:  A Cosenzi; F L Waltman; P N van Es; P W de Leeuw
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

Review 10.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.